Hematocrit Medication-Driven Changes: What Every Patient on TRT, GLP-1s, or EPO Needs to Know

What Is Hematocrit and Why Does It Matter?

Hematocrit is the fraction of whole blood made up of red blood cells, expressed as a percentage. A result of 47% means 47 mL of every 100 mL of blood is red-cell mass. The rest is plasma, white cells, and platelets. Because red cells carry oxygen, hematocrit directly reflects oxygen-delivery capacity, and both extremes of the range carry clinical risk.

Too low signals anemia, which reduces tissue oxygen delivery and causes fatigue, dyspnea on exertion, and in severe cases cardiac strain. Too high thickens blood, raises whole-blood viscosity, and increases the risk of venous thromboembolism (VTE), stroke, and myocardial infarction. The relationship between hematocrit and blood viscosity is non-linear: viscosity rises steeply above approximately 52 to 54%, which is precisely why clinical guidelines place intervention thresholds there rather than at 60% or higher.

Reference Intervals by Sex and Age

Reference intervals vary slightly across laboratories, but the WHO-aligned ranges used by most U.S. Reference labs are:

| Population | Lower limit | Upper limit | |---|---|---| | Adult men (18 to 65 yr) | 41% | 53% | | Adult women (18 to 65 yr) | 36% | 46% | | Men over 65 yr | 39% | 52% | | Women over 65 yr | 35% | 47% | | Pregnant (second trimester) | 30% | 39% |

These intervals reflect the 2.5th, 97.5th percentile of a healthy reference population and do not define optimal. The National Institutes of Health MedlinePlus resource confirms that values at the top of the "normal" band still carry meaningfully higher viscosity than mid-range values.

Optimal vs. Normal: A Distinction That Matters in Longevity Medicine

Normal means "not flagged by the lab." Optimal means the range associated with the lowest all-cause mortality and cardiovascular risk in prospective cohort data. A 2019 analysis in the Journal of the American College of Cardiology drawing on UK Biobank data (N = 502,664) found that cardiovascular mortality risk was lowest when hematocrit sat between 42 to 50% in men and 37 to 45% in women, with risk rising progressively on both sides of that band. [1] Running a hematocrit of 52% while on testosterone is technically "normal" by lab reference intervals; it is not optimal by outcomes data.

Testosterone Therapy and Hematocrit Elevation

Testosterone is the single most common medication cause of clinically significant hematocrit elevation in outpatient endocrinology and men's health practice. The effect is dose-dependent, route-dependent, and entirely predictable.

How Testosterone Raises Hematocrit

Testosterone stimulates erythropoiesis through at least two pathways. First, it directly increases renal erythropoietin (EPO) secretion. Second, it suppresses hepcidin, the liver-derived peptide that limits iron absorption, which makes more iron available for red-cell synthesis. A 2010 randomized trial by Coviello et al. (N = 61 healthy older men) showed dose-dependent increases in hematocrit of 3 to 7 percentage points over 20 weeks across testosterone doses ranging from 25 mg to 600 mg weekly. [2] The size of the hematocrit rise correlates more strongly with the peak serum testosterone concentration than with the average level, which is why long-acting injectable formulations (testosterone cypionate, testosterone enanthate) produce larger Hct elevations than daily transdermal gels at equivalent average doses.

Route-Specific Risk

Injectable testosterone creates high peak serum levels 24 to 72 hours post-injection, driving a larger erythropoietic stimulus than gels or patches. A retrospective cohort analysis by Guo et al. Published in JAMA Internal Medicine (2018) found that men on injectable testosterone were 2.3 times more likely to develop erythrocytosis (Hct above 50%) than men on transdermal formulations (adjusted OR 2.28, 95% CI 1.56 to 3.33). [3] Subcutaneous testosterone pellets also carry a higher erythrocytosis rate than gels, presumably for similar pharmacokinetic reasons.

The 54% Threshold: Where Guidelines Stand

The Endocrine Society 2018 clinical practice guideline on testosterone therapy states: "We suggest that clinicians withhold testosterone therapy if hematocrit is greater than 54%." [4] The American Urological Association (AUA) 2023 guideline on testosterone deficiency aligns with this threshold and adds that Hct should be checked at 3 to 6 months after initiation, then annually. [5]

The 54% figure is not arbitrary. It corresponds to the viscosity inflection point described by Reinhart et al. And correlates with the threshold above which VTE incidence rises sharply in observational data. Patients exceeding 54% should have testosterone withheld until Hct falls below 50%, at which point therapy can resume at a lower dose or a different route.

Managing Elevated Hematocrit on TRT

A stepwise clinical approach for hematocrit rising on TRT:

1. Rule out dehydration first. Repeat the CBC after 48 to 72 hours of adequate hydration. Dehydration can inflate Hct by 2 to 4 percentage points without any true red-cell excess.
2. Confirm the result is not a lab artifact. Prolonged tourniquet application raises measured Hct by 2 to 3%.
3. If Hct is 50 to 53%: Reduce testosterone dose by 25 to 30%, switch from injectable to transdermal, or lengthen the injection interval. Recheck in 6 to 8 weeks.
4. If Hct is 54 to 57%: Hold testosterone. Encourage vigorous hydration. Consider therapeutic phlebotomy (remove 450 to 500 mL whole blood) if symptoms of hyperviscosity are present (headache, visual changes, plethora). Recheck Hct in 4 weeks.
5. If Hct exceeds 57% or if thrombotic events occur: Refer to hematology to exclude polycythemia vera (JAK2 mutation testing). Do not restart testosterone until hematology clearance.

Therapeutic phlebotomy is effective at rapidly normalizing hematocrit but does not address the underlying erythropoietic drive. Without a dose adjustment, hematocrit will rebound within 8 to 12 weeks of a single phlebotomy session.

Erythropoiesis-Stimulating Agents

Erythropoiesis-stimulating agents (ESAs), including epoetin alfa (Epogen, Procrit) and darbepoetin alfa (Aranesp), are prescribed for anemia of chronic kidney disease (CKD), chemotherapy-induced anemia, and anemia associated with HIV therapy. They directly mimic endogenous EPO and can raise hematocrit by 8 to 15 percentage points over 4 to 8 weeks.

FDA Black-Box Warning and the TREAT Trial

The FDA's black-box warning for ESAs, updated in 2011, explicitly states that targeting hemoglobin above 11 g/dL (corresponding to roughly Hct above 33%) in CKD does not provide additional benefit and increases the risk of serious cardiovascular events and death. [6] The TREAT trial (N = 4,038, published in NEJM 2009) randomized patients with type 2 diabetes and CKD to darbepoetin alfa targeting hemoglobin of 13 g/dL vs. Placebo. The high-target group had a 2-fold increase in stroke risk (HR 1.92, 95% CI 1.38 to 2.68, P<0.001) without improvement in death or cardiovascular outcomes. [7]

Target Range in CKD

Current KDIGO 2024 guidelines recommend an ESA target hemoglobin of 10 to 11.5 g/dL for most CKD patients not on dialysis, which corresponds to approximately Hct 30 to 34%. Deliberately keeping hematocrit in the lower portion of the normal range reduces ESA-driven thrombotic risk.

GLP-1 Receptor Agonists and Hematocrit

GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), do not directly stimulate erythropoiesis. Their effect on hematocrit is indirect and largely a hemoconcentration artifact driven by reduced caloric intake, nausea-related fluid restriction, and rapid adipose mass loss in early treatment.

STEP-1 Data

In STEP-1 (N = 1,961), semaglutide 2.4 mg subcutaneous weekly produced 14.9% mean weight loss at 68 weeks vs. 2.4% with placebo. [8] Post-hoc analyses of the STEP program consistently showed transient rises in hematocrit of 1 to 3 percentage points during the first 8 to 12 weeks, normalizing thereafter as dietary intake stabilized. The signal was more pronounced in patients who also used diuretics.

Clinical Implication

A modest hematocrit rise in the first 2 to 3 months of GLP-1 therapy is expected and does not require dose reduction in the absence of other risk factors. If Hct climbs above 50% in a man or 44% in a woman on a GLP-1 agonist, the most likely explanation is concurrent dehydration or diuretic use rather than a primary hematologic problem.

Diuretics and Other Drugs That Raise Hematocrit via Hemoconcentration

Any drug that depletes plasma volume without affecting red-cell mass will raise measured hematocrit without increasing total red-cell count. This is a pseudo-polycythemia rather than true erythrocytosis.

Common Offenders

• Loop diuretics (furosemide, torsemide): Can raise Hct by 2 to 5 percentage points in patients who become volume-depleted.
• Thiazide diuretics (hydrochlorothiazide, chlorthalidone): Smaller plasma-volume effect than loop diuretics, typical Hct rise of 1 to 3 points.
• SGLT-2 inhibitors (empagliflozin, canagliflozin): Osmotic diuresis from glycosuria raises Hct by 2 to 4 points in the first weeks of therapy. A meta-analysis of SGLT-2 inhibitor trials (N = 34,987 pooled patients) reported a mean hematocrit increase of 2.5 percentage points, which partly explains their cardiovascular benefit by improving cardiac preload. [9]

Medications That Lower Hematocrit

Several common drug classes suppress erythropoiesis or increase red-cell destruction.

ACE Inhibitors and ARBs in CKD

ACE inhibitors reduce EPO production by lowering angiotensin II, which is a stimulator of EPO synthesis. In CKD patients, ACE inhibitor therapy can lower Hct by 2 to 4 points. This is pharmacologically benign in most patients but may require closer monitoring in those with baseline borderline anemia.

Chemotherapy

Myelosuppressive chemotherapy agents broadly suppress bone marrow output. Carboplatin, cisplatin, and anthracyclines are the most reliably associated with anemia. A 2016 Cochrane review found that chemotherapy-induced anemia severe enough to require red-cell transfusion or ESA therapy occurred in 30 to 60% of patients depending on the regimen. [10]

Ribavirin

Ribavirin, used historically in hepatitis C treatment and still used in some viral hemorrhagic fever protocols, causes dose-dependent hemolytic anemia. Hematocrit can fall 5 to 10 points within the first 4 weeks of therapy. Modern direct-acting antiviral regimens for hepatitis C are ribavirin-free in most patients, which has largely eliminated this clinical problem in that context.

Hydroxyurea

Hydroxyurea, used in sickle-cell disease and polycythemia vera, deliberately lowers hematocrit by inhibiting ribonucleotide reductase and slowing red-cell synthesis. In polycythemia vera, the target Hct is below 45%, which is the threshold shown to reduce major thrombotic events in the CYTO-PV trial (N = 365, published in NEJM 2013). [11]

Interpreting Hematocrit in Special Populations

Athletes and High-Altitude Residents

Chronic hypoxia, whether from altitude residence above 2,500 meters or endurance athletic training, physiologically raises hematocrit via endogenous EPO. Values of 50 to 54% in male endurance athletes are not uncommon and do not represent pathology. The World Anti-Doping Agency (WADA) uses a blood passport approach rather than a single Hct cutoff to distinguish physiologic adaptation from EPO doping. Clinical teams managing elite athletes on testosterone or peptide protocols should interpret hematocrit in the context of altitude and training load.

Patients With Sleep Apnea

Untreated obstructive sleep apnea (OSA) raises hematocrit through nocturnal hypoxia-driven EPO stimulation. A cross-sectional study published in CHEST (2015, N = 2,717) found that severe OSA was associated with a mean Hct increase of 3.1 percentage points compared with matched controls without OSA. [12] Starting CPAP therapy typically normalizes the excess erythrocytosis over 3 to 6 months. Patients on TRT with elevated hematocrit should be screened for OSA before attributing the elevation entirely to testosterone.

Patients With Hemoglobin Variants

Hemoglobin S (sickle trait) and hemoglobin C trait can alter the relationship between hematocrit and oxygen-carrying capacity. Routine Hct interpretation applies, but these patients may have disproportionately low functional oxygen delivery relative to their Hct number.

Monitoring Hematocrit on Hormone and Peptide Protocols

Consistent, protocol-driven monitoring prevents the two clinical scenarios that generate medico-legal risk: missing a rising hematocrit until it causes a thrombotic event, or over-reacting to a transiently elevated value caused by dehydration.

Recommended Monitoring Schedule

Per the Endocrine Society 2018 guideline and the AUA 2023 guideline, the minimum monitoring schedule for patients on testosterone therapy is:

• Baseline: CBC (including Hct) before first dose.
• 3 months: First follow-up CBC.
• 6 months: Second follow-up CBC if the 3-month value was 50 to 53%.
• Annually: Ongoing CBC once stable below 50%.

Patients on injectable testosterone should be tested at trough (the day of, or day before, their next scheduled injection) to avoid a pharmacokinetic peak artifact inflating the Hct reading. Testing at peak (24 to 72 hours post-injection) routinely yields results 1 to 3 points higher than the trough value.

When to Add a Workup for Secondary Causes

If hematocrit exceeds 54% despite stopping or reducing testosterone, clinicians should evaluate for:

1. Polycythemia vera (JAK2 V617F mutation, bone marrow biopsy if JAK2 negative but strong clinical suspicion).
2. Congenital erythrocytosis (EPO receptor mutations, rare).
3. Secondary EPO excess from renal cell carcinoma, hepatocellular carcinoma, or cerebellar hemangioblastoma.
4. Severe OSA (polysomnography if not previously done).

The Endocrine Society notes: "Testosterone therapy should not be initiated in men with hematocrit greater than 48% until a complete hematologic workup has been performed to exclude secondary causes." [4]